What Happened
Novo Nordisk's CagriSema is under FDA review, with a decision anticipated by late 2026. The company submitted the new drug application on December 18, 2025, based on the REDEFINE 1 and REDEFINE 2 pivotal trials. If approved, CagriSema would be the first injectable GLP-1 plus amylin combination on the market, a distinction that has kept the review under close watch across the metabolic field.
What CagriSema Is
CagriSema is a co-formulation of two components: cagrilintide 2.4 mg, a long-acting amylin analogue, and semaglutide 2.4 mg, a GLP-1 receptor agonist. The pairing brings together two distinct satiety pathways in a single product. Semaglutide supplies the GLP-1 mechanism now well established across the obesity field, while cagrilintide adds amylin-receptor signaling, a pathway that has drawn increasing research attention as a complement to incretin effects. Unlike a unimolecular agent such as amycretin, CagriSema delivers the two mechanisms as separate molecules combined in one injection.
The Regulatory Path
The NDA submission on December 18, 2025 rested on the REDEFINE 1 and REDEFINE 2 pivotal trials. Those studies form the evidentiary backbone of the application, providing the pivotal data the FDA is evaluating. With the review underway, an FDA decision is anticipated by late 2026, making CagriSema one of the more closely watched pending decisions in the category. The timing places it among a cluster of late-2026 milestones that will shape how the amylin and combination classes are understood.
The significance of a potential approval is structural. CagriSema would be the first injectable combination to pair a GLP-1 agent with an amylin analogue. That would validate the amylin pathway as a commercial complement to GLP-1, alongside the single-molecule approach Novo Nordisk is pursuing with amycretin. A first-in-class combination approval tends to open the door for others, so the decision carries implications beyond this one product.
Competitive Context
CagriSema's trajectory has not been without complication. An earlier head-to-head comparison showed Eli Lilly's Zepbound, based on tirzepatide, outperforming CagriSema. That result shaped expectations and prompted continued study of higher doses. A higher-dose version, at 2.4 mg cagrilintide and 7.2 mg semaglutide, is in an ongoing trial, with results expected around the first half of 2028. The higher-dose program signals that Novo Nordisk sees room to push the combination's efficacy further, even as the current-dose application proceeds through review. It also underscores that the competitive bar in obesity has risen quickly.
What It Means
The pending CagriSema decision is a milestone for the amylin class as much as for the product itself. Approval would establish GLP-1 plus amylin as a viable combination category, while the ongoing higher-dose work suggests the concept is still being optimized. Either way, the late-2026 decision is a key date on the field's calendar, and its outcome will inform how the industry weighs combination strategies against the leading dual and triple agonists.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.